KR102392598B1 - 삼관능성 항원-결합 분자 - Google Patents

삼관능성 항원-결합 분자 Download PDF

Info

Publication number
KR102392598B1
KR102392598B1 KR1020167030836A KR20167030836A KR102392598B1 KR 102392598 B1 KR102392598 B1 KR 102392598B1 KR 1020167030836 A KR1020167030836 A KR 1020167030836A KR 20167030836 A KR20167030836 A KR 20167030836A KR 102392598 B1 KR102392598 B1 KR 102392598B1
Authority
KR
South Korea
Prior art keywords
antigen
ser
antibody variable
gly
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167030836A
Other languages
English (en)
Korean (ko)
Other versions
KR20160143739A (ko
Inventor
멜빈 리틀레
유게네 추코프스키
마르쿠스 에저
미하엘 바이헬
토르슈텐 간트케
우베 로이슈
크리스티나 엘방거
갈 파브리체 레
Original Assignee
아피메트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50478320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102392598(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아피메트 게엠베하 filed Critical 아피메트 게엠베하
Publication of KR20160143739A publication Critical patent/KR20160143739A/ko
Application granted granted Critical
Publication of KR102392598B1 publication Critical patent/KR102392598B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020167030836A 2014-04-13 2015-04-12 삼관능성 항원-결합 분자 Active KR102392598B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14164523.4A EP2930188A1 (en) 2014-04-13 2014-04-13 Trifunctional antigen-binding molecule
EP14164523.4 2014-04-13
PCT/EP2015/057919 WO2015158636A1 (en) 2014-04-13 2015-04-12 Trifunctional antigen-binding molecule

Publications (2)

Publication Number Publication Date
KR20160143739A KR20160143739A (ko) 2016-12-14
KR102392598B1 true KR102392598B1 (ko) 2022-04-29

Family

ID=50478320

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167030836A Active KR102392598B1 (ko) 2014-04-13 2015-04-12 삼관능성 항원-결합 분자

Country Status (13)

Country Link
US (2) US20170037128A1 (cg-RX-API-DMAC7.html)
EP (2) EP2930188A1 (cg-RX-API-DMAC7.html)
JP (1) JP6635940B2 (cg-RX-API-DMAC7.html)
KR (1) KR102392598B1 (cg-RX-API-DMAC7.html)
CN (1) CN106661108A (cg-RX-API-DMAC7.html)
AU (1) AU2015249006B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016023362A2 (cg-RX-API-DMAC7.html)
CA (1) CA2945053A1 (cg-RX-API-DMAC7.html)
DK (1) DK3131928T4 (cg-RX-API-DMAC7.html)
MX (1) MX382970B (cg-RX-API-DMAC7.html)
RU (1) RU2753882C2 (cg-RX-API-DMAC7.html)
SI (1) SI3131928T2 (cg-RX-API-DMAC7.html)
WO (1) WO2015158636A1 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113549153A (zh) 2014-05-29 2021-10-26 宏观基因有限公司 三特异性结合分子和其使用方法
JP6839101B2 (ja) * 2015-06-15 2021-03-03 ヌマブ セラピューティクス アクチェンゲゼルシャフト ヘテロ二量体多重特異性抗体フォーマット
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
KR20250089564A (ko) 2017-02-08 2025-06-18 드래곤플라이 쎄라퓨틱스, 인크. 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도
KR20190120782A (ko) 2017-02-20 2019-10-24 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US20200362054A1 (en) * 2017-11-21 2020-11-19 Brian Granda Trispecific binding molecules against tumor-associated antigents and use thereof
CA3079363A1 (en) * 2017-11-21 2019-05-31 Innate Pharma Multispecific antigen binding proteins
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
PE20210375A1 (es) 2018-02-08 2021-03-02 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019175368A1 (en) * 2018-03-14 2019-09-19 Affimed Gmbh Bispecific egfr/cd16 antigen-binding protein
CN111527108A (zh) * 2018-03-27 2020-08-11 西雅图免疫公司 制导和导航控制蛋白的制造和使用方法
EP3802609A2 (en) 2018-05-24 2021-04-14 Janssen Biotech, Inc. Psma binding agents and uses thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
BR112021002276A2 (pt) 2018-08-08 2021-05-04 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
PL3843757T3 (pl) 2018-08-27 2024-08-05 Affimed Gmbh Kriokonserwowane komórki nk wstępnie obciążone konstruktem przeciwciała
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
MA55717A (fr) 2019-04-19 2022-02-23 Janssen Biotech Inc Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
CA3160927A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
US12157771B2 (en) 2020-05-06 2024-12-03 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
JP2023545099A (ja) 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
CA3200317A1 (en) * 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
JP2024504758A (ja) 2021-01-28 2024-02-01 ヤンセン バイオテツク，インコーポレーテツド Ｐｓｍａ結合タンパク質及びその使用
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
EP4376958A1 (en) 2021-07-30 2024-06-05 Affimed GmbH Duplexbodies
CN114044822B (zh) * 2021-10-28 2023-06-27 杭州博茵生物技术有限公司 血清淀粉样蛋白a抗体的重链和轻链可变区、抗体及运用
CN114316060B (zh) * 2021-12-15 2023-06-13 北京市肿瘤防治研究所 抗人cd19与cd206双特异性抗体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
WO1998003670A1 (en) * 1996-07-23 1998-01-29 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
ES2276735T3 (es) * 2001-09-14 2007-07-01 Affimed Therapeutics Ag Anticuerpos fv multimericos de cadena sencilla en tandem.
PL372144A1 (en) * 2001-12-26 2005-07-11 Immunomedics, Inc. Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains
PL1673398T3 (pl) * 2003-10-16 2011-05-31 Amgen Res Munich Gmbh Multispecyficzne deimmunizowane cząsteczki wiążące CD3
JP5399712B2 (ja) * 2005-12-21 2014-01-29 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 可溶性ｃｅａに対する抵抗性を有する医薬組成物
BRPI0910482A2 (pt) * 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
MX2011011925A (es) * 2009-05-27 2011-12-06 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos.
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
WO2012054748A2 (en) * 2010-10-22 2012-04-26 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway

Also Published As

Publication number Publication date
WO2015158636A1 (en) 2015-10-22
DK3131928T3 (da) 2020-02-24
RU2016138347A3 (cg-RX-API-DMAC7.html) 2018-12-04
AU2015249006A1 (en) 2016-10-20
JP2017513476A (ja) 2017-06-01
AU2015249006B2 (en) 2020-10-29
US20170037128A1 (en) 2017-02-09
EP3131928B1 (en) 2019-11-20
JP6635940B2 (ja) 2020-01-29
WO2015158636A8 (en) 2016-11-17
DK3131928T4 (da) 2023-05-30
CA2945053A1 (en) 2015-10-22
BR112016023362A2 (pt) 2018-03-27
MX382970B (es) 2025-03-12
RU2753882C2 (ru) 2021-08-24
EP3131928A1 (en) 2017-02-22
US20220048994A1 (en) 2022-02-17
SI3131928T1 (sl) 2020-04-30
RU2016138347A (ru) 2018-05-14
CN106661108A (zh) 2017-05-10
MX2016013218A (es) 2017-05-19
KR20160143739A (ko) 2016-12-14
SI3131928T2 (sl) 2023-05-31
EP2930188A1 (en) 2015-10-14
EP3131928B2 (en) 2023-04-05

Similar Documents

Publication Publication Date Title
KR102392598B1 (ko) 삼관능성 항원-결합 분자
JP6936497B2 (ja) 多価Ｆｖ抗体
KR102629905B1 (ko) 항-pd-l1/항-pd-1 천연 항체 구조-유사 헤테로다이머 이중특이성 항체 및 그의 제조
CN110121505A (zh) 嵌合抗原受体和表达其的自然杀伤细胞
JP2019500032A (ja) 二重特異性タンパク質複合体を用いる方法
CN114957481A (zh) 针对cd19和cd22的双靶点star
EP3969482A1 (en) Lockr-mediated recruitment of car t cells
TW202432833A (zh) 新穎ｃｄ１９結合體、包含彼之ｃａｒ—ｔ構築體及其使用方法
CN112996819B (zh) 细胞分选系统及使用方法
US20240299543A1 (en) Self-polarizing immune cells
CN116635071A (zh) 抗tspan8-抗cd3双特异性抗体和抗tspan8抗体
TW202430565A (zh) 包含與il18組合之新穎cd19結合體之car-t構築體及其使用方法
US20250312453A1 (en) Antibody targeting ccr8 and its applications
RU2785766C9 (ru) Мультивалентные fv-антитела
RU2785766C2 (ru) Мультивалентные fv-антитела
HK1260025A1 (en) Multivalent fv antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161103

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200408

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210526

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211129

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210526

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211129

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210722

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200408

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20220329

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220228

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20211129

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210722

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200408

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220426

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220427

End annual number: 3

Start annual number: 1

PG1601 Publication of registration